http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2745653-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e2546c3f3c2cf69e68544b45e52eac3b |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4166 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-345 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-341 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4166 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-345 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-341 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 |
| filingDate | 2020-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cc94c31b810ef351e269c8abcbe3c0a3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4efc4e9d611ba0793031fdf90b754328 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_312dd36e89fb331f3ab5fb8ca926d504 |
| publicationDate | 2021-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2745653-C1 |
| titleOfInvention | Method for treating dogs with mitral valve endocardiosis |
| abstract | FIELD: veterinary medicine. n SUBSTANCE: invention relates to veterinary medicine, in particular to the treatment of internal diseases in animals, and can be used for treating dogs with mitral valve endocardiosis. This is done by prescribing lifetime therapy with pimobendan at a dose of 0.25 mg/kg twice a day, telmisartan at an initial dose of 0.5 mg/kg with an increase after 14 days to 1 mg/kg per day, furosemide at a dose of 3 mg/kg twice a day intravenously to reduce chronic symptoms of cardiosvascular insufficiency followed by oral conversion, spironolactone at a dose of 2 mg/kg 2 times a day. n EFFECT: method enables reducing the symptoms of chronic cardiovascular insufficiency due to the effect of the joint use of preparations on the diastolic function, by improving the relaxation and filling of the left ventricle, and by suppressing the sympathoadrenal and renin-angiotensin-aldosterone system with a significant increase in animal life expectancy. n 1 cl, 4 tbl, 5 ex |
| priorityDate | 2020-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 68.